Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new drug combo outsmart resistant lung cancer?

NCT ID NCT07784959

Disease control Sponsor: Nuvectis Pharma, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 25, 2026 · Last updated Aug 26, 2026 · Updated 1 time

Summary

This trial is testing whether adding an experimental drug called NXP900 to the standard treatment lorlatinib can help people with advanced ALK-positive non-small cell lung cancer. The study includes adults who have already been treated with lorlatinib and whose cancer has not been cured. Researchers are looking at safety, tumor response, and how long any benefit lasts.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
NXP900 combined with lorlatinib
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced ALK-positive lung cancer whose disease has progressed on lorlatinib alone.
What could go wrong
This is an early-phase trial with a small number of participants, so the combination may not prove more effective than lorlatinib alone, and there is a risk of unexpected side effects.
Why investors are watching

Nuvectis Pharma is testing its experimental drug NXP900 together with the approved lung cancer medicine lorlatinib in 54 patients with advanced ALK-positive non-small cell lung cancer. For a micro-cap company with few products, this early-stage combination trial is a key test of whether NXP900 adds value in a real patient group. A clear signal of disease control could make the drug more attractive to larger partners or support further development.

If it works: A positive result could show that NXP900 safely combines with lorlatinib and helps control the cancer, which might strengthen the company's position in the lung cancer field. That outcome could lead to larger trials or partnership deals.

If it fails: Phase 1 trials often fail to show enough benefit or reveal safety problems, and this one is small and early. A poor result or delay could hurt the company's prospects, since it has few other products to fall back on.

AI-written from the trial record. Speculative, and not investment advice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 54 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 years old or older * Unresectable, metastatic or locally advanced ALK-positive NSCLC. * Must have received lorlatinib as first or second line TKI * One prior line of systemic chemotherapy is permitted * Must have tolerated the dose level of lorlatinib actively being explored in the study or a higher dose Exclusion Criteria: * Known single or compound ALK domain mutations that cause resistance to lorlatinib, or known actionable oncogenic driver alterations other than ALK with approved targeted therapies available, such as, MET or EGFR mutations or HER2 overexpression * Any contraindications to treatment with lorlatinib according to the lorlatinib United States Prescribing Information (USPI)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALK positive are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALK positive ALK+ non-small-cell lung carcinoma ALK-positive non-small cell lung cancer NSCLC

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • NEXT Virginia

    RECRUITING

    Fairfax, Virginia, 22031, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.